"On Rituxan subcu, I mean, we certainly expect that the same value proposition exists in a similar way for Herceptin versus Rituxan. We're just beginning to roll that out in different European countries now where we're seeing good, very good positive uptake in the 1 or 2 countries that we've exposed it to. You said whether it boost growth or not, again, the vast -- the strategy around this is not necessarily to boost growth because we're highly penetrated in these markets and it's essentially a pricing parity strategy. The strategy is rather to secure the business from potential biosimilar entrants, so that's really why we're excited also about the market share increase."
From seekingalpha.com Roche transcript.
News 
Market Data 
Discover 
